No stem cell therapy for stroke recovery has FDA approval in the United States. The EU has not licensed any cell-based stroke product as a medicinal therapy, though one neurogenic cell product received ATMP conditional approval in limited European markets. Most stroke cell therapies remain investigational or available under regulated research protocols. Regulatory pathways are evolving; positive phase III trials (expected completion 2026–2027) may accelerate approval timelines.
Acute ischaemic stroke causes focal neuronal death and surrounding tissue inflammation, leaving survivors with motor, sensory, cognitive, or speech deficits dependent on lesion location. Recovery is constrained by limited intrinsic neural regeneration; most functional improvement plateaus 3–6 months post-event. Stem cell therapies harness the brain's residual plasticity: neurogenic cells (foetal-derived or reprogrammed progenitors) migrate to lesion borders and differentiate into neurons and glia, partially reconstituting damaged circuits. Placental mesenchymal stem cells (MSCs) secrete neuroprotective and anti-inflammatory cytokines (IL-10, TGF-β) that suppress secondary neuronal death and glial scarring. Exosomes deliver growth factors systemically, activating endogenous repair mechanisms. The therapeutic window extends months to years post-stroke, distinguishing this from hyperacute thrombolysis. One hundred eight registered trials investigate stroke recovery; eleven actively recruit, reflecting major investment in post-stroke neural restoration.
Am I a candidate? → · Stroke Recovery: full overview → · Stroke Recovery cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估